title: Specificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, Colombia.
abstract: A serological test for the detection of human papillomavirus (HPV) infection in females at risk of developing cervical cancer could be based on conserved L1 peptides with low levels of antigenicity specifically recognized by antibodies from patients with cervical lesions infected with high-risk HPV (HR-HPV) types. The aim was to assess the ability of L1 peptides 18283, 18294, and 18301 compared with the ability of virus-like particles (VLPs) to identify these infections in females. A total of 391 HPV-infected female volunteers were interviewed, and peripheral blood and cervical cells were obtained for detection of anti-HPV antibodies and HPV DNA; all of the patients had a Pap smear test; 287 patients were referred for colposcopy or biopsy, according to gynecological criteria. The level of agreement, as determined by the use of the Lin coefficient (rho value), showed that 75 to 83% of females with HR-HPV DNA-positive cervical lesions had antibodies that recognized VLPs and peptide 18283, 18294, or 18301, while 15 to 23% of the HPV DNA-negative females with a normal cytology had antibodies that recognized these three peptides and 45% had antibodies that recognized VLPs. The rate of agreement between peptides and VLPs for antibody detection was higher for patients with HPV DNA-positive cervical lesions. Peptides 18283, 18294, and 18301 showed similar sensitivities for the detection of HR-HPV DNA-positive cervical lesions and were more specific than VLPs. Peptide 18301 might be detecting protective antibodies in HPV DNA-negative females with atypical squamous cells of undetermined significance. These peptides could be useful for the design of a serology test for the detection of HR-HPV infection in females with cervical lesions and at risk of cervical cancer.
authors.affiliation: Virology, Fundacion Instituto de Inmunologia de Colombia, Carrera 50, #26-00, Bogota 020304, Colombia. mauricio_urquiza@fidic.org.co
authors.forename: Mauricio
authors.initials: M
authors.lastname: Urquiza
authors.forename: Ricardo
authors.initials: R
authors.lastname: Sánchez
authors.forename: Jairo
authors.initials: J
authors.lastname: Amaya
authors.forename: Sandra
authors.initials: S
authors.lastname: León
authors.forename: Jenny
authors.initials: J
authors.lastname: Acosta
authors.forename: Manuel A
authors.initials: MA
authors.lastname: Patarroyo
authors.forename: Milena
authors.initials: M
authors.lastname: Camargo
authors.forename: Manuel E
authors.initials: ME
authors.lastname: Patarroyo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D003105:Colombia; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D006761:Hospitals; D006801:Humans; D007159:Immunologic Tests / Q000379:methods; D008875:Middle Aged; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000175:diagnosis*; D012680:Sensitivity and Specificity; D014626:Vaginal Smears; D014764:Viral Proteins; D022701:Virosomes
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral; D014764:Viral Proteins; D022701:Virosomes
references.citation: J Clin Microbiol. 1996 Sep;34(9):2095-100
references.pmid: 8862564
references.citation: Eur J Cancer. 1996 May;32A(5):872-6
references.pmid: 9081369
references.citation: Science. 1988 Jan 29;239(4839):487-91
references.pmid: 2448875
references.citation: J Clin Microbiol. 1998 Jul;36(7):2046-51
references.pmid: 9650960
references.citation: Int J Cancer. 1992 Feb 1;50(3):349-55
references.pmid: 1310487
references.citation: J Adolesc Health. 2005 Dec;37(6 Suppl):S3-9
references.pmid: 16310138
references.citation: J Infect Dis. 1995 Jul;172(1):19-24
references.pmid: 7797910
references.citation: J Clin Microbiol. 2000 Feb;38(2):688-95
references.pmid: 10655368
references.citation: J Infect Dis. 2000 Jun;181(6):1911-9
references.pmid: 10837170
references.citation: J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62
references.pmid: 9049358
references.citation: Biometrics. 1989 Mar;45(1):255-68
references.pmid: 2720055
references.citation: J Clin Virol. 2004 Aug;30(4):302-8
references.pmid: 15163418
references.citation: J Natl Cancer Inst. 1997 May 7;89(9):630-8
references.pmid: 9150187
references.citation: Int J Cancer. 2005 May 20;115(1):114-20
references.pmid: 15688414
references.citation: Clin Diagn Lab Immunol. 2002 May;9(3):577-82
references.pmid: 11986263
references.citation: Br J Cancer. 2004 Aug 31;91(5):942-53
references.pmid: 15292939
references.citation: J Virol. 2003 Nov;77(21):11625-32
references.pmid: 14557648
references.citation: Proc Natl Acad Sci U S A. 1985 Aug;82(15):5131-5
references.pmid: 2410914
references.citation: EMBO J. 2002 Sep 16;21(18):4754-62
references.pmid: 12234916
references.citation: J Gen Virol. 2004 Sep;85(Pt 9):2643-2650
references.pmid: 15302958
references.citation: Science. 1985 Dec 20;230(4732):1350-4
references.pmid: 2999980
references.citation: Virology. 1985 Aug;145(1):181-5
references.pmid: 2990099
references.citation: Rev Inst Med Trop Sao Paulo. 2003 May-Jun;45(3):131-5
references.pmid: 12870061
references.citation: Obstet Gynecol Surv. 2006 Jun;61(6 Suppl 1):S3-14
references.pmid: 16729902
references.citation: Gynecol Oncol. 2004 Mar;92(3):873-80
references.pmid: 14984955
references.citation: J Clin Virol. 2000 Oct;19(1-2):1-5
references.pmid: 11091143
references.citation: Asian Pac J Cancer Prev. 2001 Apr-Jun;2(2):135-141
references.pmid: 12718645
references.citation: J Infect Dis. 1996 Nov;174(5):927-36
references.pmid: 8896492
references.citation: Clin Diagn Lab Immunol. 1997 Mar;4(2):122-6
references.pmid: 9067643
references.citation: Cancer Lett. 2006 Jan 18;231(2):309-13
references.pmid: 16399232
references.citation: Cancer. 2006 Oct 25;108(5):288-97
references.pmid: 16952155
references.citation: Int J Cancer. 2002 Feb 20;97(6):796-803
references.pmid: 11857357
references.citation: J Virol. 2006 May;80(10):4664-72
references.pmid: 16641259
references.citation: J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71
references.pmid: 7658497
references.citation: Dermatol Clin. 2002 Apr;20(2):315-31
references.pmid: 12120445
references.citation: Biochem Biophys Res Commun. 2005 Jun 24;332(1):224-32
references.pmid: 15896321
references.citation: J Clin Virol. 2005 Mar;32 Suppl 1:S16-24
references.pmid: 15753008
references.citation: J Infect Dis. 1998 Jun;177(6):1710-4
references.pmid: 9607854